OncoMatch/Clinical Trials/NCT06376721
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Is NCT06376721 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Linperlisib and Camrelizumab for natural killer/t-cell lymphoma, nasal and nasal-type.
Treatment: Linperlisib · Camrelizumab · Pegaspargase · Dexamethasone — The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received:
refractory or relapsed after initial remission
Cannot have received: PI3K inhibitor
Patients has received PI3K inhibitor treatment before enrollment
Lab requirements
Blood counts
wbc ≥ 3×10e9/l, plt ≥ 75×10e9/l, anc ≥ 1.5×10e9/l
Kidney function
scr ≤ 1.5 mg/dl, gfr ≥ 50 ml/min
Liver function
alt & ast ≤ 3 times the upper limit of normal, tbil ≤ 2 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06376721 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PI3K inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify